Replies to post #47902 on Biotech Values

[caravon]

Avastin Plus Chemotherapy Improved PFS in Non-Squamous NSCLC numbers do not add up.

"The 22 and 33 percent improvements in PFS respectively in the 15 mg/kg and 7.5 mg/kg Avastin treatment arms can also be referred to as 18 and 25 percent reductions in risk of cancer progression or death, as calculated by the hazard ratios. Median PFS was 6.5 months in the 15 mg/kg Avastin plus chemotherapy arm, 6.7 months in the 7.5 mg/kg Avastin plus chemotherapy arm and 6.1 months in the gemcitabine/cisplatin chemotherapy alone arm."

The changes from 6.1m to 6.5m or 6.7m are 6.5% and 10% respectfully.

Looks like Genentech and Roche are "cooking" false numbers.